Nexomics provides genomic testing using bespoke targeted cancer panel tests found in solid tumour cancers.

Solid Cancers

We identify alterations or mutations in relevant genes and identify clinical treatment options including targeted therapies, and clinical trials.

We provide clinicians with a personalised and user friendly reporting that outlines the genomic findings and patient treatment options. We have panels to suit most clinical circumstances including small and large targeted panels, homologous recombination deficiency and paediatric panels that can detect not only mutation but also copy number alterations.